Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells

Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2157-63. doi: 10.1161/01.ATV.0000181744.58265.63. Epub 2005 Aug 11.

Abstract

Objective: Both advanced glycosylation end products (AGEs) and dendritic cells (DCs) have been shown to play a causative role in atherosclerosis. However, whether they function interactively in the process remains uncertain. We therefore studied the effects of AGE-bovine serum albumin (AGE-BSA) on the maturation of DCs and the expressions of scavenger receptor-A (SR-A) and receptor for AGEs (RAGE) on DCs.

Methods and results: AGE-BSA induced DCs maturation accompanied with increased expressions of CD1a, CD40, CD80, CD83, CD86, and MHC class II. The capacity of DCs to stimulate T-cell proliferation and secretion of cytokines (interferon [IFN], IFN-gamma, interleukin [IL]-10 and IL-12) was also enhanced by AGE-BSA. AGE-BSA significantly upregulated SR-A and RAGE expression on DCs and the upregulation was abolished by inhibition of mitogen-activated protein (MAP) kinase Jnk, but not by that of Erk and p38 MAP kinase. AGE-BSA-induced expression of CD83 and secretion of IL-12 were partly inhibited by either an anti-RAGE neutralizing antibody or a Jnk inhibitor.

Conclusions: AGE-BSA induces maturation of DCs and augmented their capacity to stimulate T-cell proliferation and cytokine secretions possibly through upregulation of RAGE and SR-A, which at least in part through Jnk. These findings might explain in part the interactive roles of AGEs and DCs in the processes of atherosclerosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anthracenes / pharmacology
  • Antibodies / pharmacology
  • Antigens, CD / metabolism
  • Atherosclerosis / immunology*
  • Atherosclerosis / metabolism*
  • Atherosclerosis / pathology
  • CD83 Antigen
  • Cell Communication / drug effects
  • Cell Communication / immunology
  • Cell Differentiation / drug effects
  • Cell Differentiation / immunology
  • Dendritic Cells / cytology*
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology*
  • Gene Expression / drug effects
  • Gene Expression / immunology
  • Glycation End Products, Advanced / pharmacology*
  • Humans
  • Immunoglobulins / metabolism
  • In Vitro Techniques
  • Interleukin-12 / metabolism
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / immunology
  • Membrane Glycoproteins / metabolism
  • Monocytes / cytology
  • Receptor for Advanced Glycation End Products
  • Receptors, Cell Surface / genetics
  • Receptors, Cell Surface / metabolism
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / immunology
  • Receptors, Immunologic / metabolism
  • Scavenger Receptors, Class A / genetics
  • Scavenger Receptors, Class A / metabolism
  • Serum Albumin, Bovine / pharmacology*
  • T-Lymphocytes / cytology
  • Up-Regulation / drug effects
  • Up-Regulation / immunology

Substances

  • Anthracenes
  • Antibodies
  • Antigens, CD
  • Glycation End Products, Advanced
  • Immunoglobulins
  • Membrane Glycoproteins
  • Receptor for Advanced Glycation End Products
  • Receptors, Cell Surface
  • Receptors, Immunologic
  • Scavenger Receptors, Class A
  • advanced glycation end products-bovine serum albumin
  • Interleukin-12
  • pyrazolanthrone
  • Serum Albumin, Bovine
  • JNK Mitogen-Activated Protein Kinases